Marginal zone lymphoma

The EU has approved 1 indication of 1 drug in marginal zone lymphoma. None of them needs a biomarker result.

Line of therapy

Approved indications, Marginal zone lymphoma
DrugBiomarker requirementRegimenSettingConditions
No biomarker required1
Zanubrutinib
Brukinsa
None
Monotherapy
2L
After at least one prior anti-CD20-based therapy
Label wording1

The sentence from section 4.1 of the SmPC that each indication above comes from.

  1. Zanubrutinib (Brukinsa)
    BRUKINSA as monotherapy is indicated for the treatment of adult patients with marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based therapy.